Liquid biopsy company Harbinger Health said it raised $140m in a series B financing round, which brings the firm one step closer to achieving its goal of launching its first product in 2025.
The funding, announced on 28 September, comes from Flagship Pioneering, which financed Harbinger’s launch in December 2021 with $50m in committed capital. The financing round also included new global institutional...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?